Novartis said it would sell parts of its Sandoz generic-drugs business in the U.S. in a deal worth up to $1 billion, the latest move by its new chief executive to refocus the Swiss pharmaceuticals giant.
from WSJ.com: US Business https://ift.tt/2wLXpAi
via IFTTT
No comments:
Post a Comment